SCHEMBL6709044

SCHEMBL6709044

Cc1nocc1C(=O)Nc1ccccn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.59
ALDH1A1 P00352 1/20 0.59
ALOX15 P16050 1/20 0.59
NPC1 O15118 9/20 0.57
RAB9A P51151 9/20 0.57
SMN1; SMN2 Q16637 6/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
KDM4E B2RXH2 1/20 0.56
TP53 P04637 3/20 0.55
GAA P10253 1/20 0.55
CHRNB2 P17787 1/20 0.52
CHRNB4 P30926 1/20 0.52
CHRNA3 P32297 1/20 0.52
CHRNA4 P43681 1/20 0.52
CYP1A2 P05177 1/20 0.50
PKM P14618 1/20 0.50
ATM Q13315 1/20 0.50
PDE10A Q9Y233 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6707975 0.79 MEN1 (0.51) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
SCHEMBL1518716 0.78 MAPK10 (0.60) PDE10A
SCHEMBL13162953 0.77 MEN1 (0.69) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
SCHEMBL6707940 0.77 NPC1 (0.52) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
SCHEMBL6707256 0.77 MEN1 (0.52) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
Hydrochloric Acid SCHEMBL30416720 0.76 MEN1 (0.67) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
SCHEMBL27508819 0.75 RAB9A (0.70) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
SCHEMBL6710865 0.74 ALDH1A1 (1.00) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
SCHEMBL6707864 0.74 NPC1 (0.58) L3MBTL1ALDH1A1ALOX15NPC1RAB9A
SCHEMBL27474427 0.74 NPC1 (0.63) L3MBTL1ALDH1A1ALOX15NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders SUGEN, INC. 2004-05-27 US disclosed
US-6649635-B2 For therapy of cancer SUGEN, INC. 2003-11-18 US disclosed
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders MCMAHON GERALD (US) 2002-05-30 US disclosed
EP-1012150-A4 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN INC (US) 2002-05-29 EP disclosed
US-6316479-B1 ANTICANCER AGENTS SUGEN, INC. 2001-11-13 US disclosed
EP-1012150-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS Sugen, Inc. (US) 2000-06-28 EP disclosed
WO-1998052944-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN, INC. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC L3MBTL1 1271/4885ALDH1A1 3956/4885ALOX15 4365/4885
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC L3MBTL1 1271/4885ALDH1A1 3956/4885ALOX15 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.